News
SUPN
27.51
-0.94%
-0.26
Weekly Report: what happened at SUPN last week (0520-0524)?
Weekly Report · 1d ago
Stifel Nicolaus Sticks to Its Hold Rating for Supernus Pharmaceuticals (SUPN)
TipRanks · 4d ago
Piper Sandler Sticks to Its Buy Rating for Supernus Pharmaceuticals (SUPN)
TipRanks · 4d ago
SUPERNUS ANNOUNCES PROMISING INTERIM DATA FROM ONGOING OPEN-LABEL PHASE 2A STUDY OF SPN-817 IN EPILEPSY
Reuters · 4d ago
SUPERNUS PHARMACEUTICALS INC: SPN-817 DISCONTINUATION RATE DUE TO ADVERSE EVENTS (AES) OF 22% IN TITRATION PERIOD AND 2.4% IN MAINTENANCE PERIOD
Reuters · 4d ago
SUPERNUS PHARMACEUTICALS INC: SPN-817 WAS SAFE AND HAD ACCEPTABLE TOLERABILITY
Reuters · 4d ago
Weekly Report: what happened at SUPN last week (0513-0517)?
Weekly Report · 05/20 11:17
Catalyst Watch: AI in the spotlight with Nvidia earnings, Microsoft Build, and an IBM event
Seeking Alpha's Catalyst Watch looks at next week's key events. Options trading volume is elevated on Faraday Future Intelligent and AMC Entertainment. The most overbought stocks in the S&P 500 are Etsy and Zeta. Microsoft will host a showcase for new Surface hardware and AI in Windows 11. IBM will hold its American Thoracic Conference on May 17, 2024 in New York. Notable companies are due to report on May 20 and 21.
Seeking Alpha · 05/17 19:00
Weekly Report: what happened at SUPN last week (0506-0510)?
Weekly Report · 05/13 11:29
Supernus Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Supernus Pharmaceuticals Inc reports quarterly adjusted earnings of 26 cents per share for the quarter ended in March. Revenue fell 6.6% to $143.64 million from a year ago. The company reported quarterly income of $124 thousand. Supernus shares had fallen by 8.2% this quarter.
Reuters · 05/09 16:56
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
Supernus Pharmaceuticals will hold a webcast and conference call on May 23, 2024 to review interim data from the open-label Phase IIa study of SPN-817 for treatment-resistant seizures. The company is a biopharmaceutical company focused on the treatment of central nervous system diseases.
Barchart · 05/09 15:05
Piper Sandler Remains a Buy on Supernus Pharmaceuticals (SUPN)
TipRanks · 05/09 10:54
Supernus Pharmaceuticals, Inc. Form 10-Q Quarterly Report for the Quarterly Period Ended March 31, 2024
Press release · 05/09 05:59
SUPN Stock Earnings: Supernus Pharmaceuticals Misses Revenue for Q1 2024
Supernus Pharmaceuticals just reported results for the first quarter of 2024. The company did not report any EPS for the quarter. Supernus reported revenue of $143.64 million. This was 1.50% worse than the analyst estimate of $145.83 million.
Investorplace · 05/09 02:56
Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics
NASDAQ · 05/08 23:00
Supernus Pharmaceuticals Q1 Sales $143.600M Miss $145.832M Estimate
Benzinga · 05/08 21:21
Supernus Pharmaceuticals reports mixed Q1 results; reaffirms FY24 outlook
Supernus Pharmaceuticals reports mixed Q1 results; reaffirms FY24 outlook. Reiterates full year 2024 financial guidance of $580 million to $620 million. Q1 revenue of $143.6 million misses by $2.23 million; Q1 GAAP EPS of $0.00 beats by $1.08.
Seeking Alpha · 05/08 20:56
SUPERNUS PHARMACEUTICALS Q1 ADJUSTED OPERATING EARNINGS USD 22.3 MILLION VS. IBES ESTIMATE USD 22.9 MILLION
Reuters · 05/08 20:05
SUPERNUS PHARMACEUTICALS INC: REITERATES FULL YEAR 2024 FINANCIAL GUIDANCE
Reuters · 05/08 20:05
*Supernus Pharmaceuticals 1Q Rev $143.6M >SUPN
Dow Jones · 05/08 20:05
More
Webull provides a variety of real-time SUPN stock news. You can receive the latest news about Supernus Pharma through multiple platforms. This information may help you make smarter investment decisions.
About SUPN
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.